Impact of Nesiritide Infusion on Early Postoperative Recovery After Total Cavopulmonary Connection Surgery

  • Yajuan Zhang
  • Yabing Duan
  • Jun Yan
  • Qiang Wang
  • Shoujun Li
  • Haitao Xu
Original Article



The purpose of the study is to compare the effects of nesiritide on the discharge time and pleural effusion in children with total cavopulmonary connection (TCPC), and to provide a more reasonable clinical method for these children.


Forty-four who children underwent cavopulmonary connection between January 2016 and 2017 were retrospectively collected, and 5 children were excluded from analysis due to postoperative thrombosis or second Fontan surgery due to high pulmonary hypertension. Thirteen children received nesiritide (3–11 days) plus conventional treatment as the nesiritide group, continuous infusion of nesiritide with the dose of 0.01 ug kg−1 min−1. Twenty-six children with the conventional treatment as the conventional treatment group. The length of stay in hospital and the retention time of chest drainage tube were compared between two groups.


There were no significant differences in the time of cardiopulmonary bypass, postoperative ventilation time, ICU time, and vasoactive inotropic drug scores in the two groups. There were no hospital deaths in two groups. The median hospital stay was 20 days in the nesiritide group (11–56 days, means 25 days), and the median length of hospital stay was 28 days in the routine treatment group (9–95 days, means 34 days). There is no statistically significant difference between two groups with regard to the length of stay in hospital (P = 0.281). Regarding the thoracic drainage duration, the median was 17 days (9–55 days, means 22 days) in the nesiritide group and 23 days in the conventional treatment group (7–91 days, means 31 days) (P = 0.294). All the patients had no severe complications such as excessive fluid load, intractable hypotension, and liver or kidney injury.


Nesiritide is safe in children who underwent cavopulmonary connection surgery. Compared with the conventional treatment group, postoperative nesiritide is not associated with improved early clinical outcomes after TCPC surgery.


Total cavopulmonary connection Nesiritide Thoracic drainage 



We gratefully acknowledge the role of all our colleagues involved in the care of these study patients.


There was no funding supporting this study.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all patients, parents, or guardians included in the study.


  1. 1.
    Cetta F, Feldt RH, O’Leary PW et al (1996) Improved early morbidity and mortality after Fontan operation: the Mayo Clinic experience, 1987 to 1992. J Am Coll Cardiol 28:480–486CrossRefPubMedGoogle Scholar
  2. 2.
    Dabal RJ, Kirklin JK, Kukreja M et al (2014) The modern Fontan operation shows no increase in mortality out to 20 years: a new paradigm. J Thorac Cardiovasc Surg 148:2517–2524CrossRefPubMedGoogle Scholar
  3. 3.
    Driscoll DJ, Offord KP, Feldt RH et al (1992) Five- to fifteen-year follow-up after Fontan operation. Circulation 85:469–496CrossRefPubMedGoogle Scholar
  4. 4.
    d’Udekem Y, Iyengar AJ, Galati JC et al (2014) Redefining expectations of long-term survival after the Fontan procedure: twenty-five years of follow-up from the entire population of Australia and New Zealand. Circulation 130(11 Suppl 1):S32–S38CrossRefPubMedGoogle Scholar
  5. 5.
    Khairy P, Fernandes SM, Mayer JE Jr et al (2008) Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation 117:85–92CrossRefPubMedGoogle Scholar
  6. 6.
    Bartz PJ, Driscoll DJ, Dearani JA et al (2006) Early and late results of the modified Fontan operation for heterotaxy syndrome: 30 years of experience in 142 patients. J Am Coll Cardiol 48:2301–2305CrossRefPubMedGoogle Scholar
  7. 7.
    Jensen KT, Carstens J, Pedersen EB (1998) Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol 274(1 Pt 2):F63–F72PubMedGoogle Scholar
  8. 8.
    D’Souza SP, Yellon DM, Martin C et al (2003) B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 284:H1592–H1600CrossRefPubMedGoogle Scholar
  9. 9.
    Kuga H, Ogawa K, Oida A, Taguchi I et al (2003) Administration of atrial natriuretic peptide attenuates reperfusion phenomena and preserves left ventricular regional wall motion after direct coronary angioplasty for acute myocardial infarction. Circ J 67:443–448CrossRefPubMedGoogle Scholar
  10. 10.
    Prescribing information, nesiritide (Natrecor). Scios 2009 (package insert).
  11. 11.
    Colucci WS, Elkayam U, Horton DP, Nesiritide Study Group, et al (2000) Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 343:246–253CrossRefPubMedGoogle Scholar
  12. 12.
    Mentzer RM Jr, Oz MC, Sladen RN et al (2007) Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. J Am Coll Cardiol 49:716–726CrossRefPubMedGoogle Scholar
  13. 13.
    Seghaye MC, Duchateau J, Bruniaux J et al (1997) Endogenous nitric oxide production and atrial natriuretic peptide biological activity in infants undergoing cardiac operations. Crit Care Med 25:1063–1070CrossRefPubMedGoogle Scholar
  14. 14.
    Costello JM, Backer CL, Checchia PA et al (2005) Effect of cardiopulmonary bypass and surgical intervention on the natriuretic hormone system in children. J Thorac Cardiovasc Surg 130:822–829CrossRefPubMedGoogle Scholar
  15. 15.
    Sun LS, Dominguez C, Mallavaram NA et al (2005) Dysfunction of atrial and B-type natriuretic peptides in congenital univentricular defects. J Thorac Cardiovasc Surg 129:1104–1110CrossRefPubMedGoogle Scholar
  16. 16.
    Stewart JM, Gewitz MH, Clark BJ et al (1991) The role of vasopressin and atrial natriuretic factor in postoperative fluid retention after the Fontan procedure. J Thorac Cardiovasc Surg 102:821–829PubMedGoogle Scholar
  17. 17.
    Hiramatsu T, Imai Y, Takanashi Y et al (1999) Time course of endothelin-1 and adrenomedullin after the Fontan procedure. Ann Thorac Surg 68:169–172CrossRefPubMedGoogle Scholar
  18. 18.
    Mainwaring RD, Lamberti JJ, Carter TL et al (1995) Renin, angiotensin II, and the development of effusions following bidirectional Glenn and Fontan procedures. J Card Surg 10:111–118CrossRefPubMedGoogle Scholar
  19. 19.
    Takata Y, Hirayama Y, Kiyomi S et al (1996) The beneficial effects of atrial natriuretic peptide on arrhythmias and myocardial high-energy phosphates after reperfusion. Cardiovasc Res 32:286–293CrossRefPubMedGoogle Scholar
  20. 20.
    O’Connor CM, Starling RC, Hernandez P et al (2011) Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365(1):32–43CrossRefPubMedGoogle Scholar
  21. 21.
    Mahle WT, Cuadrado AR, Kirshbom PM et al (2005) Nesiritide in infants and children with congestive heart failure. Pediatr Crit Care Med 6:543–546CrossRefPubMedGoogle Scholar
  22. 22.
    Simsic JM, Scheurer M, Tobias JD et al (2006) Perioperative effects and safety of nesiritide following cardiac surgery in children. J Intensive Care Med 21:22–26CrossRefPubMedGoogle Scholar
  23. 23.
    Jefferies JL, Price JF, Denfield SW et al (2007) Safety and efficacy of nesiritide in pediatric heart failure. J Card Fail 13:541–548CrossRefPubMedGoogle Scholar
  24. 24.
    Simsic JM, Mahle WT, Cuadrado A, Kirshbom PM et al (2008) Hemodynamic effects and safety of nesiritide in neonates with heart failure. J Intensive Care Med 23:389–395CrossRefPubMedGoogle Scholar
  25. 25.
    Costello JM, Dunbarmasterson C, Allan CK et al (2014) Impact of empiric nesiritide or milrinone infusion on early postoperative recovery after Fontan surgery: a randomized, double-blind, placebo-controlled trial. Circ Heart Fail 7:596–604CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pediatric Cardiac Surgery, National Center for Cardiovascular Disease and Fuwai Hospital, Chinese Academy of Medical SciencesPeking Union Medical CollegeBeijingPeople’s Republic of China

Personalised recommendations